HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Association-European Dialysis and Transplant Association Registry.

AbstractBACKGROUND:
This study describes the incidence and outcomes of European patients requiring renal replacement therapy (RRT) for kidney failure due to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
STUDY DESIGN:
Cohort study.
SETTING & PARTICIPANTS:
12 renal registries providing individual RRT patient data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry in 1993-2012 participated.
PREDICTOR:
Cause of primary kidney disease: AAV (ie, granulomatosis with polyangiitis [Wegener] and microscopic polyangiitis) versus 3 separate matched control groups without AAV: (1) primary glomerulonephritis, (2) diabetes mellitus, and (3) disease other than diabetes mellitus as the cause of primary kidney disease, including glomerulonephritis (termed "nondiabetes").
OUTCOMES:
Incidence, causes of death, and survival.
MEASUREMENTS:
ERA-EDTA primary renal disease codes.
RESULTS:
2,511 patients with AAV (1,755, granulomatosis with polyangiitis; 756, microscopic polyangiitis) were identified, representing an incidence of 1.05 per million population (pmp) for granulomatosis with polyangiitis (predominating in Northern Europe) and 0.45 pmp for microscopic polyangiitis (prevailing in Southern Europe). Kidney transplantation was performed in 558 (22.2%) patients with vasculitis. The 10-year probability for survival on RRT after day 91 was 32.5% (95% CI, 29.9%-35.1%) in patients with vasculitis. Survival on RRT after day 91 did not differ between AAV and matched nondiabetes patients. Patient and transplant survival after kidney transplantation, adjusted for time period and country, was better in AAV than in matched nondiabetes patients (HRs of 0.81 [95% CI, 0.67-0.99] and 0.82 [95% CI, 0.69-0.96], respectively).
LIMITATIONS:
No data for extrarenal manifestations, treatment, and relapses.
CONCLUSIONS:
Geographical differences in the incidence of RRT for kidney failure due to granulomatosis with polyangiitis and microscopic polyangiitis copied their distribution in the general population. Overall survival on RRT after day 91 for patients with AAV was similar to that for patients with nondiabetes diagnoses. Our results suggest that patients with AAV are suitable candidates for kidney transplantation with favorable survival outcomes.
AuthorsZdenka Hruskova, Vianda S Stel, David Jayne, Knut Aasarød, Johan De Meester, Agneta Ekstrand, Kathrin Eller, James G Heaf, Andries Hoitsma, Carmen Martos Jimenéz, Pietro Ravani, Christoph Wanner, Vladimir Tesar, Kitty J Jager
JournalAmerican journal of kidney diseases : the official journal of the National Kidney Foundation (Am J Kidney Dis) Vol. 66 Issue 4 Pg. 613-20 (Oct 2015) ISSN: 1523-6838 [Electronic] United States
PMID25975963 (Publication Type: Evaluation Study, Journal Article)
CopyrightCopyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
Topics
  • Adult
  • Case-Control Studies
  • Cause of Death
  • Disease Progression
  • Disease-Free Survival
  • Europe
  • Female
  • Granulomatosis with Polyangiitis (diagnosis, mortality, therapy)
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Failure, Chronic (diagnosis, mortality, therapy)
  • Kidney Function Tests
  • Kidney Transplantation (methods, mortality)
  • Male
  • Microscopic Polyangiitis (diagnosis, mortality, therapy)
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Registries
  • Renal Dialysis (methods, mortality)
  • Severity of Illness Index
  • Societies, Medical
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: